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Thyroid cancer, a fairly uncommon form of
cancer in the human population, has causal
links to environmental radiation exposures
(Meirmanov et al. 2003). Although there are
multiple epidemiology studies that associate
radiation exposure with thyroid cancer, there
have been no studies to associate human thy-
roid cancer with environmental chemical expo-
sures (Hard 1998). The human thyroid
responds toxicologically to multiple anti-
thyroid drugs, including excess iodide, propyl-
thiouracil (PTU), and thionamides, but the
progression to cancer after repetitive adminis-
tration has not been observed (Hard 1998;
Hill et al. 1998; Markou et al. 2001). In con-
trast, multiple antithyroid drugs administered
to the rat have demonstrated an increase in
thyroid tumors, including PTU, thionamides,
and the hepatic enzyme inducer phenobarbital
(PB) (Capen 1997; Hurley et al. 1998;
McClain et al. 1988). Other xenobiotics,
including several organic iodides such as amio-
darone and erythrosine, have also been associ-
ated with thyroid tumor development in the
rat. Many organic iodides alter rat thyroid
homeostasis, causing thyroid hypertrophy and
alterations in colloid that may potentially lead
to thyroid tumors after chronic administration
(Capen 1997; Hurley et al. 1998).
The mechanisms by which organic iodides
induce thyroid toxicity are varied and may
include excess iodide being released into the
blood during xenobiotic metabolism, toxicity
to the liver that alters thyroid hormone
metabolism, and/or direct thyroid toxicity that
inhibits the release of thyroid hormones into
the circulation (Capen 1997; Hurley et al.
1998). In subchronic toxicology studies it has
been difﬁcult to predict whether early changes
in thyroid pathology could lead to thyroid can-
cer in the rat after chronic administration of
organic iodides. Excess iodide alone can be
toxic to thyroid cells in culture and cause thy-
roid hypertrophy and changes in colloid
in vivo in the rat model (Capen 1997; Vitale
et al. 2000). It has also been reported that
administration of excess iodide promotes thy-
roid tumor development in rats initiated with
N-bis(2-hydroxypropyl)-nitrosamine (Kanno
et al. 1992). However, iodide excess alone has
not been sufﬁcient in inducing follicular cell
hyperplasia and thyroid tumors in rats but
more commonly causes hypothyroidism
(Backer and Hollowell 2000; Kanno et al.
1994). This is believed to be due partly to the
escape from the Wolff-Chaikoff effect (acute
inhibition of iodine organiﬁcation) that is seen
within days of exposure to excess iodide (Wolff
and Chaikoff 1948). This escape phenomenon
is associated with the down-regulation of the
sodium iodide (NaI) symporter (NIS) thereby
reducing the amount of inorganic iodine in the
thyroid so that thyroxine (T4) and thyroid-
stimulating hormone (TSH) secretions are
returned to normal physiological levels (Eng
et al. 1999).
Chronic elevation of TSH levels has been
associated with an increased risk of thyroid
tumors in the rat, which may be due, in part, to
the high turnover of the circulating thyroid
hormone triiodothyronine (T3) in this species
compared with the lower T3 turnover rate in
humans (Capen 1997). Many antithyroid
drugs and PB mediate their carcinogenic prop-
erties by elevating circulating TSH levels in the
rat albeit by different mechanisms (Hood et al.
1999; McClain et al. 1988). Although PTU
reduces thyroid hormone production by
inhibiting thyroglobulin organiﬁcation in the
thyroid and inhibiting the peripheral conver-
sion of T4 to active T3, PB reduces circulating
T4 by increasing its hepatic metabolism and
excretion via glucoronidation. Reductions in
thyroid hormone (T4 and T3) by either mecha-
nism causes an elevation in TSH that is sufﬁ-
cient in causing thyroid tumors in rats after
prolonged exposure without any evidence of
thyroid DNA damage (McClain 1992).
Organic iodides may also increase TSH levels
by similar mechanisms; however, it is unknown
what contribution iodide excess has in their
overall toxicity to the rat thyroid. To this end
we have implemented biochemical, pathologi-
cal, and molecular analyses to characterize the
rat thyroid response to three model toxicants:
excess iodide by using NaI a noncarcinogen,
and the rodent thyroid carcinogens PB and
PTU, in a modiﬁed 2-week endocrine battery
(O’Connor et al. 2002). The goals of this study
were to identify dose-dependent gene expres-
sion proﬁles induced by excess iodide in rats,
determine whether gene expression profiles
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Organic iodides have been shown to induce thyroid hypertrophy and increase alterations in colloid in
rats, although the mechanism involved in this toxicity is unclear. To evaluate the effect that free iodide
has on thyroid toxicity, we exposed rats for 2 weeks by daily gavage to sodium iodide (NaI). To com-
pare the effects of compounds with alternative mechanisms (increased thyroid hormone metabolism
and decreased thyroid hormone synthesis, respectively), we also examined phenobarbital (PB) and
propylthiouracil (PTU) as model thyroid toxicants. Follicular cell hypertrophy and pale-staining col-
loid were present in thyroid glands from PB-treated rats, and more severe hypertrophy/colloid
changes along with diffuse hyperplasia were present in thyroid glands from PTU-treated rats. In PB-
and PTU-treated rats, thyroid-stimulating hormone (TSH) levels were signiﬁcantly elevated, and both
thyroxine and triiodothyronine hormone levels were signiﬁcantly decreased. PB induced hepatic uri-
dine diphosphate-glucuronyltransferase (UDPGT) activity almost 2-fold, whereas PTU reduced
hepatic 5´-deiodinase I (5´-DI) activity to < 10% of control in support of previous reports regarding
the mechanism of action of each chemical. NaI also signiﬁcantly altered liver weights and UDPGT
activity but did not affect thyroid hormone levels or thyroid pathology. Thyroid gene expression
analyses using Affymetrix U34A GeneChips, a regularized t-test, and Gene Map Annotator and
Pathway Proﬁler demonstrated signiﬁcant changes in rhodopsin-like G-protein–coupled receptor
transcripts from all chemicals tested. NaI demonstrated dose-dependent changes in multiple oxidative
stress–related genes, as also determined by principal component and linear regression analyses.
Differential transcript profiles, possibly relevant to rodent follicular cell tumor outcomes, were
observed in rats exposed to PB and PTU, including genes involved in Wnt signaling and ribosomal
protein expression. Key words: excess iodide, gene expression, microarrays, oxidative stress, pheno-
barbital, propylthiouracil, thyroid, Wnt signaling. Environ Health Perspect 113:1354–1361 (2005).
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and pathological end points in rats, and deter-
mine whether proﬁles are predictive of the car-
cinogenic potential of each chemical in rats.
Materials and Methods
In Vivo Studies
Adult male Crl:CD (SD)IGS BR rats, approx-
imately 8 weeks of age, were treated with NaI,
PB, and PTU for 14 consecutive days. NaI,
PB, and PTU were purchased from Sigma
Chemical Company (St. Louis, MO). Rats
(n = 20/group) were dosed by oral gavage with
vehicle (water or 0.25% methylcellulose),
NaI (0.1, 1, 10, or 100 mg/kg/day), PB
(100 mg/kg/day), or PTU (10 mg/kg/day) at a
dose volume of 5 mL/kg. NaI was dissolved in
water, whereas PB and PTU were dissolved in
methylcellulose. On day 15, all rats were
euthanized by carbon dioxide anesthesia and
exsanguination. Blood samples were collected
from the inferior vena cava of each animal at
necropsy to measure serum levels of TSH, T4,
T3, and reverse T3 (rT3). Terminal body, thy-
roid gland, and liver weights were recorded for
the ﬁrst 10 animals of each dose group. The
thyroid gland and surrounding tissue from the
first 10 animals of each dose group were
processed for histopathological evaluation. A
liver sample from the first five animals of
each dose group was processed to measure 5´-
deiodinase I (5´-DI) and uridine diphosphate-
glucuronyltransferase (UDPGT) activity.
Thyroid glands from the last 10 animals (ﬁve
from methylcellulose group) from each dose
group were removed and placed in RNALater
(Ambion, Austin, TX) overnight at 4°C. The
next day, thyroids were removed from the
RNALater and stored at –80°C until
processed for total RNA.
The research described in this publication
was conducted in a laboratory accredited by
the Association for the Assessment and
Accreditation of Laboratory Animal Care
International, and the investigators complied
with the regulations and standards of the
Animal Welfare Act and adhered to the prin-
ciples of the Guide for the Care and Use of
Laboratory Animals (National Research
Council 1996).
Pathological Evaluations
After euthanization the thyroid glands and
surrounding tissue from the first 10 animals
from each group were removed and placed
into formalin ﬁxative for at least 48 hr before
trimming and weighing. After fixation, one
individual performed a ﬁnal dissection under
a dissecting microscope. This was done in
order to reduce the variability of the dissec-
tion procedure, thereby reducing the variabil-
ity of the thyroid gland weights. Organ
weights were calculated relative to body
weight. The formalin-fixed thyroid glands
were examined microscopically.
Hormonal Measurements
Blood was collected at the time of euthaniza-
tion from all animals. Serum was prepared and
stored between –65°C and –85°C until ana-
lyzed for serum hormone concentrations.
Serum TSH (Amersham Biosciences Corp.,
Piscataway, NJ), T3 and T4 (Diagnostic
Products Corp., Los Angeles, CA), and rT3
(Polymedco Corp., Cortlandt Manor, NY)
concentrations were measured using commer-
cially available RIA kits.
Microsomal Preparations
At necropsy, a section of the liver from the
first five animals from each group was
removed, and hepatic microsomes were pre-
pared for biochemical evaluation. A portion of
the liver was homogenized (1 g tissue/8 mL
buffer) in buffer containing 50 mM
Tris–HCl, 0.25 M sucrose, and 5.4 mM
EDTA, pH 7.4. The homogenates were cen-
trifuged at 15,000 × g for 15 min at 4°C. The
resulting supernatants were removed and cen-
trifuged at 100,000 × g for 70 min at 4°C;
these pellets contained the microsomal frac-
tions. The microsomal pellets were re-
suspended in the homogenization buffer at a
protein concentration of 10–20 mg/mL,
aliquoted, and stored between –65°C and
–85°C until analyzed for UDPGT and 5´-DI.
The protein content of the microsomes was
measured before and after analyses by the
BioRad method (Bradford 1976). Final calcu-
lations were based on the postassay protein
determination.
5´-Deiodenase I Measurements
Microsomal 5´-DI activity was determined
using modiﬁcations of the methods of Pazos-
Moura et al. (1991) and Leonard and
Rosenberg (1980). Brieﬂy, 50 µL of reaction
mixture [0.1 M potassium phosphate, 1 mM
EDTA, 0.5 mM DTT, 14.5 µL [125I]rT3
(~ 4.9 µCi, 0.05 nmol)] was preincubated at
37°C for approximately 1 min. Fifty micro-
liters of microsomes, diluted with liver
homogenization buffer to achieve a ﬁnal pro-
tein concentration of 0.5 mg/mL, was added
to the reaction mixture. The tubes were vor-
texed and incubated for 10 min at 37°C. The
reaction was stopped by the addition of 33 µL
of ice-cold BSA–PTU solution (4% BSA,
5 mM PTU) and 133 µL of 20% TCA, and
the tubes were placed on ice until centrifuga-
tion. All tubes were centrifuged for 3 min at
12,000×g, 4°C. Two hundred microliters of
the resulting supernatant (75% of the reaction
volume) was applied to a Poly-Prep column
equilibrated with 10% acetic acid, and eluted
with 1.7 mL of 10% acetic acid. The resulting
eluate was measured on a gamma counter to
determine 5-DI activity (nmoles [125I]rT3
deiodinated per hour per milligram protein).
UDPGT Measurements
Microsomal UDPGT activity was determined
spectrophotometrically using a modiﬁcation of
the method of Bock et al. (1983). Briefly,
15 µL of p-nitrophenol (66.7 mM) was added
to 460 µL of microsomes, which had been
resuspended with assay buffer [66 mM
Tris–HCl, 10 mM magnesium chloride,
0.05% Brij 58 (polyoxyethylene ether 2 cetyl
ether; CAS no. 9004-95-9), pH 7.5] to
achieve a final protein concentration of
0.5–1.0 mg/mL. The tubes were preincubated
at 37°C for 2 min before the addition of 25 µL
UDPGA (uridine diphosphate glucuronic acid;
200 mM) to start the reaction. The tubes were
vortexed and incubated for 10 min at 37°C. A
reaction blank tube for each sample was run
concurrently by substituting the UDPGA with
assay buffer. The reaction was stopped by the
addition of 0.5 mL ice-cold methanol, and the
tubes were placed on ice until centrifugation.
All tubes were centrifuged for 10 min at
2,000×g at 4°C. Three hundred microliters of
the supernatant was combined with 2.7 mL
0.1 N sodium hydroxide, and the absorbance
at 405 nm was measured. Rate of UDPGT
activity is expressed as nmoles per minute per
milligram protein.
Microarray Analysis
RNA preparation and analysis was done
according to the Affymetrix-recommended pro-
tocol (Affymetrix 2002). Briefly, total RNA
from four animals from each dose group was
prepared individually using the TRIzol pro-
cedure (Invitrogen, Carlsbad, CA) and cleaned
using the Qiagen RNeasy mini RNA cleanup
protocol (Qiagen, Valencia, CA). The integrity
of each RNA sample was determined using an
Agilent 2100 Bioanalyzer (Agilent, Foster City,
CA). After this, double-stranded cDNA from
three of the four samples was prepared from
16 µg of total RNA using Superscript II reverse
transcriptase (Invitrogen) and a T7 primer
(Genset, Boulder, CO) for first-strand syn-
thesis, and DNA polymerase and ligase
(Invitrogen) for second-strand synthesis.
Subsequently, labeled cRNA was synthesized
from the cDNA using the Enzo RNA transcript
labeling kit (Affymetrix, Santa Clara, CA)
according to the manufacturer’s instructions.
Approximately 20 µg of biotin-labeled cRNA
was then fragmented in a solution of 40 mM
Tris–acetate, pH 8.1, 100 mM KOAc, and
30 mM MgOAc at 94°C for 35 min. Labeled
cRNA was hybridized to the Affymetrix
GeneChip Test2 Array (Affymetrix) to verify
the quality of labeled cRNA. After this, cRNA
was hybridized to the Affymetrix Rat Genome
U34A GeneChip Probe Array (RG-U34A;
Affymetrix). The cRNA in hybridization
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while rotating in a hybridization oven. After
approximately 16 hr of hybridization, the
cocktail was removed and the arrays were
washed and stained in a Fluidics Station 400
(Affymetrix) according to the Affymetrix-
recommended protocol (Affymetrix 2002).
Brieﬂy, several cycles of washes were done ini-
tially with a nonstringent buffer (1 M NaCl,
67 mM NaH2PO4, 6.7 mM EDTA, 0.01%
Tween 20) at 25°C and then with stringent
buffer [100 mM MES, 0.1 M Na+, 0.01%
Tween 20] at 50°C. The arrays were then
stained in streptavidin phycoerythrin (SAPE)
solution (10 µg/mL SAPE, 2 mg/mL acety-
lated BSA, 100 mM MES, 1 M Na+, 0.05%
Tween 20) at 25°C, washed in nonstringent
buffer, stained in antibody solution (2 mg/mL
acetylated BSA, 100 mM MES, 1 M [Na+],
0.05% Tween 20, 0.1 mg/mL normal goat
IgG, 3 µg/mL anti-streptavidin biotinylated
antibody) at 25°C, stained again in SAPE
solution at 25°C, and then washed again in
nonstringent buffer at 30°C. Arrays were then
scanned on a GeneArray scanner (Agilent).
Image analysis, quantification of raw gene
expression values, mismatched probe back-
ground subtraction, and present/absent calls
were performed using the Microarray Suite
software (version 5.0; Affymetrix).
Data Analysis
Differential gene expression was determined
by the regularized t-test, which uses a
Bayesian procedure (Baldi and Long 2001).
Briefly, the expression level of each gene is
assumed to be from a normal distribution
with µ and σ2. Using a conjugate prior, the
mean of the posterior (MP) estimate of µ is
the sample mean. The MP estimate of σ2 is 
where n is the sample size, s2 is the sample vari-
ance, v0 is the degrees of freedom of the prior
(a value of 10 is used in the analysis), and σ0
2
is the mean of sample variances of genes in the
neighborhood of the gene under consideration.
The neighborhood is the 50 genes with sample
means immediately above and below the sam-
ple mean of the gene under consideration; that
is, the neighborhood consists of the 101 genes
centered on the gene. After the MP estimates
of µ and σ2 are obtained, the t-test of unequal
variances is used to calculate a p-value of differ-
ential expression.
Multiple linear regressions are used to
determine dose-dependent expression after NaI
treatments of 0.1, 1, 10, or 100 mg/kg/day.
Some genes respond to NaI linearly, but for
other genes, the induction or repression of
expression may become saturated after some
dose levels. Therefore, two types of multiple
linear regressions were performed. The first
type was the linear regression of the gene
expression levels and the dose levels, and the
other type was the linear regression of the 
gene expression levels and the logarithms of the
dose levels.
A principal component analysis was also
performed on the data. Three animals were
measured within each treatment for each gene.
The treatment means were then subjected to
principal component analysis. The compo-
nents were thus determined on a per-treatment
basis rather than a per-gene basis, as in
Raychaudhuri et al. (2000). For each of the
treatments, the mean of the transcription sig-
nals was computed. Then, for each treatment,
the ratio of the treatment mean to the corre-
sponding control mean was computed. The
logarithms of these six signal ratios were then
analyzed. There was no need to standardize
these log-ratios, because they were essentially
standardized without further attention.
Results
Liver Weights and Hormone
Metabolism
After the 2-week exposure period, liver weights
were increased in a dose-dependent manner
and were signiﬁcantly higher in rats adminis-
tered 10 and 100 mg/kg/day NaI (8–13%
increase) and 100 mg/kg/day PB (44%
increase) compared with control rats that
received water alone (Figure 1). Liver weights
were slightly reduced in animals that received
10 mg/kg/day PTU, and this was attributed to
concomitant reductions in body weight in this
treatment group (data not shown).
UDPGT activity was signiﬁcantly higher
(99% increase) in rats administered 100 mg/
kg/day PB compared with controls (Figure 1).
In contrast, UDPGT activity was reduced
(28% decrease) in rats that received 100 mg/
kg/day NaI for 2 weeks. 5´-DI activity was
dramatically reduced in PTU-treated animals
(93% decrease), whereas all other treatments
had no signiﬁcant change in activity compared
with controls (Figure 1).
Thyroid Hormone Levels 
and Histopathology
Treatment-related effects on thyroid hormone
levels were observed in the 100 mg/kg/day PB
and 10 mg/kg/day PTU groups. Compared
with controls, T3, T4, and rT3 levels were
reduced 23, 40, and 28%, respectively, in PB-
treated rats and 80, 99, and 56%, respec-
tively, in PTU-treated rats (Table 1). TSH
levels were increased approximately 2- and
4-fold in PB- and PTU-treated rats, respec-
tively. There were no treatment-related effects
on thyroid hormone levels observed with NaI
at any concentration tested.
Treatment-related changes in thyroid gland
histopathology were observed in the PB and
PTU treatment groups (Table 2). Thyroid fol-
licular cell hypertrophy and pale-staining col-
loid were observed in both PB and PTU
treatment groups, and diffuse hyperplasia was
observed in the PTU group. Relative thyroid
σ
νσ
ν
2 00
22
0
1
2
=
+ −
+ −
()
,
ns
n
Glatt et al.
1356 VOLUME 113 | NUMBER 10 | October 2005 • Environmental Health Perspectives
Liver weight 5´-DI UDPGT
14
12
10
8
6
4
2
0
Control
NaI (0.1)
NaI (1)
NaI (10)
NaI (100)
PB
PTU
#
#
#
*
* **
**
Figure 1. Hepatic metabolism parameters: mean ± SD of 5–10 measurements from individual animals. Liver
weight is expressed as percent body weight. 5´-DI activity is expressed as nmol [125I]rT3 deiodinated/hr/mg
protein. UDPGT activity is expressed as nmol/min/mg protein/10. 
*Signiﬁcant by least signiﬁcant difference. **Signiﬁcant by least signiﬁcant difference and Dunnett’s test. #Signiﬁcant by
Dunnett/Tamhane-Dunnett test.
Table 1. Thyroid hormone parameters.
Treatment (mg/kg/day) T3 (ng/mL) T4 (ng/mL) TSH (ng/dL) rT3 (ng/mL)
Water 73.6 ± 12.5 4.23 ± 0.83 12.2 ± 6.1 0.111 ± 0.015
NaI (0.1) 75.6 ± 12.4 4.37 ± 0.92 10.7 ± 3.6 0.118 ± 0.018
NaI (1) 69.0 ± 10.5 4.40 ± 1.01 11.5 ± 4.2 0.114 ± 0.022
NaI (10) 68.9 ± 10.4 4.38 ± 1.29 15.1 ± 7.8 0.106 ± 0.023
NaI (100) 73.3 ± 14.4 4.58 ± 1.14 13.1 ± 5.0 0.106 ± 0.020
PB (100) 56.5 ± 10.4* 2.52 ± 0.84* 22.4 ± 10.2* 0.080 ± 0.024*
PTU (10) 14.5 ± 7.3* 0.04 ± 0.10* 51.9 ± 12.4* 0.049 ± 0.018*
Values represent mean ± SD of 16 or more measurements from individual animals in each group. 
*Statistical signiﬁcance from control as determined by Jonckheere-Terpstra trend test, p < 0.05. gland weights (percent of body weight) were
also significantly increased (~ 3-fold) in the
PTU treatment group compared with controls
(Table 2). No treatment-related changes in thy-
roid gland histopathology were observed after
NaI administration at any of the doses tested.
Thyroid Gland Gene Expression
Principal component analysis. Thyroid gene
expression data were analyzed using principal
component analysis, a regularized t-test and
multiple linear regressions. Principal compo-
nent analysis of gene expression data from all
24 samples demonstrated grouping according
to treatment. Six principal components were
identified (Table 3). Of these, the first four
account for approximately 85% of the total
variation in the data. Neither of the remaining
two meets the 70/N rule used by Raychaudhuri
et al. (2000). The general methodology of that
reference was followed in the present analysis.
To understand these principal components, it is
helpful to express each as a linear combination
of the means of the six treatments (Table 4).
The ﬁrst component is essentially the average of
the NaI treatment log-signal ratios. Large values
of this component tend to be associated with
up-regulation in one or more NaI treatments.
Large negative values (i.e., negative numbers
large in absolute value) of this component
tend to be associated with down-regulation in
one of more NaI treatments. The second com-
ponent is an indicator for an effect due to PB
and PTU. A large value of Pcomp2 (principal
component 2) indicates an up-regulation,
whereas a large negative value indicates a down-
regulation. Component 3 is primarily a contrast
between the PB and PTU treatments. The
fourth principal component is primarily an
indicator of effect at low doses of NaI. Based on
these principal component analysis findings,
further gene ontology work was directed to the
first two principal components, namely,
genomic proﬁles associated with NaI exposure
or PB and PTU exposure.
Multiple linear regressions. Dose-dependent
expression, as determined by multiple linear
regressions, was observed after NaI treatment.
Transcript levels most influenced by dose
(p ≤ 0.001), included the NIS [Slc5a5;
GenBank accession no. U60282; (http://
www.ncbi.nlm.gov)] and antioxidant enzymes
such as glutathione peroxidase 2 (Gpx2),
thioredoxin reductase (Txnrd1), and glu-
tathione S-transferase pi (GST-pi; Gstp2)
(Table 5). NIS mRNA was down-regulated in
a dose-dependent manner to 80 (not statisti-
cally signiﬁcant), 40, 30, and 20% of control
values after 0.1, 1, 10, and 100 mg/kg/day
NaI, respectively (Figure 2A). However,
unlike NaI, PTU increased NIS expression by
greater than 300% of control, and PB only
slightly reduced (70% of control) NIS tran-
script levels. The most statistically signiﬁcant
of the antioxidant enzymes, GST-pi, was
up-regulated to 154, 196, 263, and 250% of
control values after the same NaI dosing regi-
men (Figure 2B). Similar to NaI, PB and
PTU increased GST-pi expression levels to
198 and 265% of control, respectively.
Regularized t-test (Bayesian procedure). In
a separate analysis using the regularized t-test,
872, 948, and 1552 gene transcripts (of 8,740
transcripts present in all samples) were signiﬁ-
cantly (p < 0.01) changed by 100 mg/kg/day
NaI, 100 mg/kg/day PB, and 10 mg/kg/day
PTU administration compared with controls,
respectively. To further characterize these
genomic changes according to biological func-
tion and identify molecular pathways involved
in the mode of action of each chemical, these
gene lists were uploaded into GenMAPP
(Gene Map Annotator and Pathway Proﬁler,
version 1.0; Dahlquist et al. 2002). Two molec-
ular pathways found to be highly inﬂuenced by
NaI were rhodopsin-like G-protein receptors
and oxidative-stress–related genes (Table 5).
These pathways were also inﬂuenced by PB and
PTU treatment, although the spectrum of gene
transcripts was unique for each chemical.
Although all chemicals affected the expression
of one or more adrenergic receptors, dopa-
mine and chemokine receptor transcripts were
only affected by PB and PTU treatment,
respectively. PB and PTU also caused a down-
regulation of TSH receptor mRNA (Table 5)
correlating with the increased circulating TSH
observed with these chemicals from the serum
hormone analysis. Interestingly, NaI induced
speciﬁc changes in multiple olfactory receptor
and oxidative stress transcripts, including
Txnrd1, Gpx2, superoxide dismutase 2 (Sod2),
and nitric oxide synthase 2 (Nos2), that were
not affected by PB or PTU treatment
(Table 5). NaI also altered the levels of multiple
transcripts involved in apoptosis that were not
affected by PB or PTU treatment including
receptor-interacting serine-threonine kinase 3
[Ripk3, GenBank accession no. AF036537
(http://www.ncbi.nlm.nih.gov)], BH3 interact-
ing domain 3 [Bid3; GenBank accession no.
AI102299 (http://www.ncbi.nlm.nih.gov)],
and scavenger receptor class B [Scarb1;
GenBank accession no. D89655 (http://www.
ncbi.nlm.nih.gov); p < 0.001]
To further identify discriminating molecu-
lar pathways that might be predictive of thyroid
pathology and cancer risk, additional emphasis
was placed on molecular pathways affected by
both PB and PTU but not NaI. Interestingly,
large differences were observed in transcripts
from ribosomal protein and Wnt signaling gene
families. Although not observed after NaI expo-
sure, multiple 40S ribosomal protein transcripts
were significantly reduced by PTU and PB
treatment, including S4 (Rps4), S6 (Rps6), and
S8 (Rps8) proteins (Table 6). NaI-dependent
changes in ribosomal transcripts were observed
in the large 60S subunit that included L22
(Rpl22) and L18 (Rpl18a) ribosomal proteins.
Wnt target gene transcripts cyclin D1 (Ccnd1),
c-jun (Jun), insulin-like growth factor binding
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Table 2. Thyroid gland pathology.
Treatment (mg/kg/day) Thyroid (g) Colloid Hypertrophy Hyperplasia
Water 0.006 ± 0.001 – – —
NaI (100) 0.007 ± 0.002 – – —
PB (100) 0.007 ± 0.001 + + —
PTU (10) 0.018 ± 0.003* ++ ++ ++
Abbreviations: –, no lesions observed; +, lesions observed; ++, severe lesions observed. Values represent mean ± SD of
9–11 measurements from individual animals in each group. 
*Statistical signiﬁcance from control as determined by least signiﬁcant difference and Dunnett’s test, p < 0.05.
Table 3. Principal component analysis.
Principal component Eigenvalue Proportion Cumulative
1 2.53220382 0.4220 0.4220
2 1.36004986 0.2267 0.6487
3 0.69452426 0.1158 0.7645
4 0.51077061 0.0851 0.8496
5 0.49305017 0.0822 0.9318
6 0.40940129 0.0682 1.0000
Table 4. Principal component values based on treatment group.
Variable Pcomp1 Pcomp2 Pcomp3 Pcomp4 Pcomp5 Pcomp6
Lnsigrat3 0.491944 –0.079240 0.067459 0.816707 –0.153903 –0.237625
Lnsigrat5 0.502641 –0.050801 0.241487 –0.396262 0.480074 –0.546773
Lnsigrat7 0.494279 0.023657 0.208137 –0.391877 –0.721315 0.194792
Lnsigrat9 0.498959 –0.063955 –0.394606 –0.007669 0.406380 0.652712
Lnsigrat11 0.109047 0.688894 –0.627580 –0.063206 –0.133869 –0.312667
Lnsigrat13 0.013435 0.715482 0.586721 0.135445 0.206111 0.287812
Abbreviations: Lnsigrat#, natural logarithm of the transcription signal ratio for treatment number; Pcomp#, principal com-
ponent number. protein (Igfbp2), VEGF receptor (Kdr), and
protein kinase C (PKC) ζ (Prkcz) were up-
regulated 50–300% in thyroids from PB- and
PTU-treated animals, whereas no treatment-
related changes in these transcripts were
observed after NaI exposure (Table 6; Figure 3).
PTU also altered the expression of other Wnt
target genes, including multiple cyclin D3
(Ccnd3) transcripts and urokinase plasminogen
activator receptor (Plau) mRNA (Table 6,
Figure 3). Decreased expression of the adeno-
matous polyposis coli (Apc) gene and/or its
homologs was also observed after exposure to
PB and PTU. Finally, a modest increase (40%)
in frizzled protein (Fzd1) mRNA was observed
on a single gene target from the NaI treatment
group. Multiple protein kinase transcripts were
affected by PB and/or PTU exposure, including
the up-regulation of Prkcz (PB and PTU) and
PKCα (Prkca), and down-regulation of protein
kinase A [Prkaa; GenBank accession no.
X57986 (http://www.ncbi.nlm.nih.gov); PTU
only]. In contrast, NaI did not significantly
alter the transcript levels of any protein kinase
(Table 6; Figure 3).
Discussion
Many organic iodides alter rat thyroid home-
ostasis that may potentially lead to thyroid
tumors after chronic administration (Capen
1997; Hurley et al. 1998). Although chemi-
cally induced changes in thyroid hormone
metabolism and thyroid hormone release have
been associated with increased thyroid tumor
incidence in rodents, no such correlation with
cancer risk has been associated with excess
iodide (Capen 1997; Markou et al. 2001). To
better characterize thyroid toxicity associated
with increased cancer risk in the rat, genomic,
clinical, and pathological end points were
examined in response to excess NaI (non-
carcinogen) and the rodent thyroid carcino-
gens PB and PTU in a modified 2-week
endocrine battery (O’Connor et al. 2002).
Similar to previous reports, PB and PTU
caused hormonal alterations (reduced serum
T3, rT3, and T4 levels and increased TSH) and
induced thyroid follicular cell hypertrophy in
male rats after a 2-week exposure period
(De Sandro et al. 1991). PB also increased rela-
tive liver weights (percent of body weight) and
hepatic UDPGT activity, suggesting the
involvement of altered thyroid hormone
metabolism in PB-induced thyroid toxicity
(Barter and Klassen 1992). In contrast, PTU
reduced hepatic 5´-DI activity, increased rela-
tive thyroid weights (percent body weight),
and induced thyroid follicular cell hyperplasia
in male rats, suggesting an alternative mecha-
nism of toxicity, including peripheral conver-
sion of T4 to T3 (Oppenheimer et al. 1972).
These effects elicited by PB and PTU in this
short-term study, speciﬁcally, increases in TSH
levels resulting in microscopic alterations of the
thyroid gland, are suggestive of a potential thy-
roid tumor response after longer-term expo-
sures in male rats (Capen 1997).
No biologically significant effects were
observed after NaI exposure using the same
treatment regimen. NaI caused no changes in
thyroid hormone levels or thyroid histo-
pathology. UDPGT activity was statistically
significantly reduced in rats dosed with
100 mg/kg/day NaI, although liver weights
were significantly increased in male rats
receiving 10 and 100 mg/kg/day NaI. The
significance of these effects on hepatic
UDPGT activity is unclear but suggests an
alternative effect on liver metabolism despite
the concomitant increase in liver weights.
Glatt et al.
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Table 5. Treatment-related effects on rhodopsin-like G-protein–coupled receptor and oxidative
stress–related gene expression.
GenBank
Gene group/namea Gene symbola accession no.a NaI PB PTU
Rhodopsin-like GPCRs
Alpha-1D adrenergic receptor Adra1d M60654 —c 1.6 3.0
Alpha-1B adrenergic receptor Adra1b M60655 2.0 2.1 3.4
Alpha-1C adrenergic receptor Adra1c U13368 –2.1 —c —c
Alpha-2A adrenergic receptor Adra2a U79031 1.9 — —
Beta-2 adrenergic receptor Adrb2 J03024 2.9 — —
Beta-3 adrenergic receptor Adrb3 S56481 –2.2 — –2.1
Serotonin receptor 6 Htr6 S62043 –1.6 — —
Serotonin receptor 4 Htr4 U20907 — — 4.1
Serotonin receptor 1F Htr1f L05596 — 7.7 —
Serotonin receptor 7 Htr7 L22558 — — 2.5
Dopaminergic receptor D-3 Drd3 A17753 — 3.4 —
Opioid receptor mu-1 Oprm1 D16349 — –2.7 —
Cholinergic receptor muscarinic 3 Chrm3 M16407 — — –1.7
Cholinergic receptor muscarinic 5 Chrm5 M22926 –1.9 — —
Neuropeptide Y5 receptor Npy5r U66274 2.1 — —
Panceatic polypeptide receptor Ppyr1 U42388 –2.1 — —
Interleukin 8 receptor beta Il8rb U70988 — — –2.0
Chemokine receptor 4 Cxcr4 U90610 — — 1.9
Chemokine receptor 1 Cx3cr1 U04808 — — 2.1
A3 adenosine receptor —b X93219 –2.8 — —
Angiotensin II receptor — M90065 — — –1.8
Angiotensin II receptor (AT1B) — X64052 — –3.7 —
Thyroid-stimulating hormone receptor Tshr M34842 — –1.6 –1.7
Chemokine orphan receptor 1 Cmkor1 AJ010828 1.5 — —
Endothelin receptor type B Ednrb X57764 — — 1.6
Prostaglandin E receptor 4 Ptger4 D28860 — — 3.0
Platelet-activating factor receptor Ptafr U04740 — — 2.6
Bradykinin receptor B1 Bdkrb1 AJ132230 –1.4 — —
GABAB receptor 1 Gabbr1 AB016161 –1.6 — —
Olfactory receptor pseudogene Olr1469 AF091570 –1.3 — —
Olfactory receptor 1696 Olr1696 AF034896 –1.7 — —
Olfactory receptor 1699 Olr1699 AF034899 –2.9 — —
Olfactory receptor 226 Olr226 M64386 — — –1.9
Olfactory receptor 1361 Olr1361 M64377 –2.0 — —
Olfactory receptor 1370 Olr1370 AF091577 –2.2 — —
Olfactory receptor 1493 Olr1493 AF091572 –2.4 — —
Olfactory receptor 1346 Olr1346 AF091578 –4.2 — —
Olfactory receptor 1687 Olr1687 AF091563 –5.3 –3.6 —
Oxidative stress–related genes
NAD(P)H dehydrogenase quinone Nqo1 J02679 2.2 1.5 2.0
Heme oxygenase 1 Hmox1 J02722 1.9 2.0 —
Glutamate-cysteine ligase Gclc J05181 1.5 1.5 —
Thioredoxin reductase 1 Txnrd1 U63923 1.5 — —
Glutathione peroxidase 1 Gpx1 X07365 1.4 — 1.4
Glutathione peroxidase 2 Gpx2 AA800587 2.4 — —
Glutathione reductase Gpr U73174 — 1.6 1.6
GST-pi Gstp2 X02904 2.5 2.0 2.6
Superoxide dismutase 3 Sod3 X68041 –1.4 — 1.7
Superoxide dismutase 2 Sod2 Y00497 1.6 — —
Superoxide dismutase 1 Sod1 M25157 –2.0 — —
Metallothionein-1a Mt1a M11794 –1.7 –1.9 –2.1
Peroxiredoxin 1 Prdx1 AI010083 1.2 — —
Nitric oxide synthase 2 Nos2 U16359 2.2 — —
Cytochrome b-245 alpha Cyba U18729 1.7 — 1.6
Monoamine oxidase A — S45812 — — –1.4
Values represent statistically signiﬁcant (p< 0.01 by regularized t-test) mean fold change from control (n= 3) for 100 mg/kg/day
NaI and PB and 10 mg/kg/day PTU.
aFrom GenBank (http://www.ncbi.nlm.nih.gov). b—, Gene symbol unknown. c—, Not statistically signiﬁcant. These dose-dependent effects demonstrate for
the first time that excess iodide can elicit a
biological/toxicological response on the liver.
The importance of these observed liver effects
are also supported by the fact that iodide
doses used in this study (1–10 mg/kg/day) are
obtainable in high-dose toxicology studies
with iodinated compounds.
We found multiple gene transcripts that
were signiﬁcantly altered by linear regression,
regularized t-test, and principle component
analysis models in response to NaI treatment.
The transcripts most sensitive to iodide expo-
sure included the thyroid NIS and GST-pi.
NIS mRNA was signiﬁcantly reduced to 40%
of control levels at NaI doses as low as
1 mg/kg/day. A similar reduction in NIS
mRNA has been reported previously after
6 days of exposure to 0.05% NaI in the drink-
ing water of rats (Eng et al. 1999). In that
study a concomitant reduction in protein level
was also demonstrated suggestive of reduced
iodide transport into the thyroid. In our
study, GST-pi mRNA was significantly
increased (150% of control) in the thyroid of
rats exposed to the lowest dose of NaI tested
(0.1 mg/kg/day). The biologic signiﬁcance of
increased GST-pi (Gstp2) transcripts in the rat
thyroid is uncertain but may be predictive of
increased oxidative stress. Other antioxidant
gene transcripts were induced in the rat thy-
roid after NaI exposure, including Gpx1 and
Gpx2 (1.4- and 2.4-fold, respectively), Sod2
(1.6 fold), Txnrd1 (1.5-fold), heme oxygenase
(Hmox1, 1.9-fold), and NAD(P)H dehydro-
genase quinone (Nqo1, 2.2-fold; Table 5).
Iodide increases oxidative stress in cultured
thyroid cells as evidenced by increased intra-
cellular reactive oxygen species and lipid per-
oxidation (Vitale et al. 2000). It has been
suggested that I2, the molecular form of ionic
iodide, is highly reactive with protein, lipids,
and nucleic acids and that generation of
iodocompounds may disrupt cellular mem-
brane functions, increase reactive oxygen
species, and cause programmed cell death in
thyroid cells. Dose-dependent increases in the
antioxidant enzyme transcripts Gpx2 and
Gstp2 observed in the rat thyroid are consis-
tent with a compensatory response to the gen-
eration of lipid peroxides as reported by Vitale
et al. (2000) using iodide exposures in vitro.
The observed alterations in multiple tran-
scripts involved in apoptosis in our studies are
also consistent with this proposed mechanism
of iodide-induced thyroid toxicity.
NaI exposure also inﬂuenced the mRNA
expression of a wide range of rhodopsin-like
G-protein–coupled receptors including adren-
ergic receptors. NaI increased β-adrenergic
receptor (Adrb2) gene expression in a dose-
dependent manner, whereas PB and PTU
increased α1-adrenergic receptor (Adra1d)
gene expression. In previous in vitro studies,
thyrotropin (TSH) increased α1-adrenergic
receptor mRNA in rat thyroid FRTL-5 cells as
a compensatory mechanism to down-regulate
TSH-induced cAMP levels (Corda and Kohn
1985). cAMP is considered the primary sec-
ond messenger in thyroid follicular cell growth
and maintenance (Medina and Santisteban
2000; Richards 2001). Together with the
observed reduction in TSH receptor mRNA
observed in the thyroids of rats exposed to PB
Gene expression profiles of rat thyroid toxicity
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Table 6. Treatment-related effects on Wnt signaling and ribosomal protein gene expression.
GenBank
Gene group/namesa Gene symbola accession no.a NaI PB PTU
Wnt signaling genes 
APC fragment 2 of 6 —b L19304c —d –1.6 —d
APC fragment 4 of 6 — L19306 — –2.2 –2.6
APC protein Apc D38629 — — –2.0
c-jun oncogene Jun X17163 — 2.9 2.3
Cyclin D1 Ccnd1 D14014 — 1.4 2.6
Cyclin D1 partial Ccnd1 X75207c — 1.3 2.3
Cyclin D3 Ccnd3 D16309c — 1.4 1.7
Cyclin D3 partial Ccnd3 U49935c — 1.6 1.7
Frizzled homolog 1 Fzd1 L02529 1.5 — —
DNA damage inducible transcript Gadd45a L32591 — –1.7 –2.0
Insulin-like factor binding protein Igfbp2 M91595 — 1.7 5.2
Low-density lipoprotein receptor Ldlr X13722 — — 2.1
p38 MAP kinase Mapk14 U91847 — 1.6 —
p38 MAP kinase 2 Mapk14 U73142 — — 1.4
Protein kinase C, alpha Prkca X07286 — — 3.7
Protein kinase C, zeta Prkcz M18332 — 1.6 1.4
Plasminogen activator, urokinase Plau X63434 — — –1.8
VEGF receptor 2 Kdr U93306 — 1.9 2.8
Ribosomal protein genes
Ribosomal protein S5 Rps5 X58465 — — –1.4
Ribosomal protein S4 Rps4 X14210 — –1.4 –1.4
Ribosomal protein S6 Rps6 M29358 — –1.5 –1.2
Ribosomal protein S9 Rps9 X66370 — — –1.3
Ribosomal protein S8 Rps8 X06423 — –1.3 –1.3
Ribosomal protein S7 Rps7 X53377 — — –1.3
Ribosomal protein S3 Rps3 X51536 — — –1.3
40 kDa ribosomal protein Lamr1 D25224 — — –1.3
v-fos transformation effector Rps3a M84716 — –1.6 –1.2
Ribosomal protein L3 Rpl3 X62166 — — –1.4
Ribosomal protein L5 Rpl5 M17419 — –1.5 —
Ribosomal protein L9 Rpl9 X51706 — — –1.4
Ribosomal protein L10 Rpl10 X93352 — — –1.4
Ribosomal protein L11 Rpl11 X62146 — — –1.4
Ribosomal protein L12 Rpl12 X53504 — — –1.4
Ribosomal protein L14 Rpl14 X94242 — — –1.3
Ribosomal protein L17 Rpl17 X58389 — — –1.4
Ribosomal protein S25 Rps25 X62482 — — –1.4
Ribosomal protein L7 Rpl7a X15013 — — –1.3
Ribosomal protein L18 Rpl18a X14181 –1.4 — —
Ribosomal protein L21 Rpl21 M27905 — –1.4 –1.4
Ribosomal protein L22 Rpl22 X60212 –2.1 — –1.8
Ribosomal protein L23 Rpl23 X65228 — — –1.5
Ribosomal protein L26 Rpl26 X14671 — — –1.4
Ribosomal protein L28 Rpl28 X52619 — — –1.3
Ribosomal protein L37 Rpl37 X66369 — — —
Values represent statistically significant (p < 0.01 by regularized t-test) mean fold change from control (n = 3) for
100 mg/kg/day NaI and PB and 10 mg/kg/day PTU.
aFrom GenBank (http://www.ncbi.nlm.nih.gov). b—, Gene symbol not known. cp ≤ 0.03 by regularized t-test. d—, Not statisti-
cally signiﬁcant.
* *
*
3299
±139
*
*
*
*
**
**
**
**
1,400
1,200
1,000
800
600
400
200
0
S
i
g
n
a
l
 
i
n
t
e
n
s
i
t
y
Treatment (mg/kg/day)
Water NaI
(0.1)
NaI
(1)
NaI
(10)
NaI
(100)
Vehicle PB
(100)
PTU
(10)
4,000
3,500
3,000
2,500
2,000
1,500
1,000
500
0
S
i
g
n
a
l
 
i
n
t
e
n
s
i
t
y
Treatment (mg/kg/day)
Water NaI
(0.1)
NaI
(1)
NaI
(10)
NaI
(100)
Vehicle PB
(100)
PTU
(10)
A B
Figure 2. Bar graph of dose-dependent NIS (A) and GST-pi (B) gene expression. Values represent mean ± SD
of three measurements from individual animals. 
Signiﬁcantly different at *p < 0.05 from water and **p < 0.05 from vehicle controls by regularized t-test.Glatt et al.
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and PTU, these gene expression changes are
suggestive of an adaptive response to high lev-
els of circulating TSH seen in rats treated with
PB and PTU but not NaI. Further investiga-
tion is needed to understand the biological sig-
nificance, if any, of β-adrenergic receptor
mRNA induction by NaI.
To further identify gene expression
changes that may be predictive of cancer risk,
additional emphasis was placed on signaling
pathways influenced by PB and PTU (car-
cinogens) but not NaI (noncarcinogen).
Interestingly, signiﬁcant changes were observed
in gene expression patterns associated with
Wnt signaling in PB and PTU exposed ani-
mals. Up-regulation of Ccnd1, Ccnd3, and Jun
mRNA (all transcriptional targets of Wnt sig-
naling) are suggestive of increased risk to
human cancer (Behrens 2000; Ishigaki et al.
2002). Cyclin D1 protein is overexpressed in
human thyroid cancers that have causal links
to environmental radiation exposures at
nuclear test sites (Meirmanov et al. 2003).
Cyclin D1 and cyclin D3 both facilitate entry
into the cell cycle, and increased transcription
of these genes is associated with increased cell
proliferation and hyperplasia (Baldassarre et al.
2003; Ishigaki et al. 2002). Thyroid hyperpla-
sia was only observed in PTU animals and not
PB animals (hypertrophy was observed in both
groups), suggesting that increased expression of
these genes precedes visible histopathological
changes. Finally, the proto-oncogene Jun,
which is also associated with multiple types of
human cancer, mediates its oncogenic activity
by stimulating AP-1–mediated transcription
and cell proliferation (Shaulian and Karin
2001). Up-regulation of Jun has been associ-
ated with thyroid cancer, but its importance in
mediating Wnt signaling in the thyroid has yet
to be characterized (Battista et al. 1998).
Increased β-catenin protein is a common
marker for Wnt signaling in multiple types of
cancer, including thyroid cancer (Behrens
2000). β-Catenin complexes with the adeno-
matous polyposis coli (Apc) gene and axin to
regulate its phosphorylation by glycogen syn-
thase kinase (Gsk3b) and subsequent proteo-
somal degradation (Henderson and Fagotto
2002). Wnt activation inhibits the phosphory-
lation of β-catenin, resulting in its nuclear accu-
mulation, binding to the lymphoid enhancer
factor-1/T-cell–specific transcription factor
(LEF-1/TCF), and transcription of multiple
target genes as previously discussed (Kikuchi
2000). Interestingly, signiﬁcantly lower gene
expression levels of Apc and/or two other tumor
suppressor proteins with homologous sequence
mRNAs were observed in the thyroid glands of
animals treated with PB and PTU but not NaI.
In addition, mRNA expression of Prkcz, an
inhibitor of Gsk3b kinase activity, was up-regu-
lated in response to PB and PTU animals but
not NaI (Oriente et al. 2001). Inhibition of
Gsk3b results in decreased phosphorylation of
β-catenin and causes its nuclear accumulation.
Lastly, a DNA damage protein (Gadd45a) and
a MAP kinase (Mapk14), two other proteins
recently associated with Wnt activation, were
also differentially expressed in PB- and PTU-
treated animals but not in NaI-treated animals
(Hildesheim et al. 2004).
In further support of our ﬁndings, recent
investigations have also demonstrated silencing
of Wnt signaling in mammalian cells after
exposures to thyroid hormone (T3; Miller et al.
2001; Natsume et al. 2003). In these studies
T3 inhibited β-catenin accumulation and
transcriptional activity in rat pituitary and
human kidney cells, respectively. Although T3
promotes cellular growth in many cellular sys-
tems, it is suggested that T3 involvement in
normal organ development and cellular differ-
entiation also implies antitumor activity of this
critical hormone. In our studies, reductions in
thyroid hormone were only observed in PB-
and PTU-treated animals with the most sig-
niﬁcant changes after PTU exposure. This cor-
relates well with the magnitude and number of
Wnt signaling target genes changed in the
microarray analyses of each treatment group.
Finally, significant changes in ribosomal
protein mRNA were also observed in PB- and
PTU-exposed animals. Alterations in ribosomal
protein expression have been associated with
increased cell proliferation and hyperplasia in
multiple tissue types (Chou and Blenis 1995;
Hamadeh et al. 2002). The ribosomal protein
Rps6, regulated by p70 ribosomal S6 kinase
(pp70s6k), is important in transcription and
translation events precluding entry into the cell
cycle (Cass and Meinkoth 1998). The mRNA
of this protein was down-regulated in PB- and
PTU-treated animals, correlating with other
cAMP signaling responses (protein kinase
mRNA regulation) observed in this study.
In summary, we present new findings
with regard to thyroid gene expression in the
rat after subchronic exposure to NaI, PB, and
PTU. Although no significant changes in
biochemical and pathological measurements
of thyroid function were observed in the rat
after NaI exposure, significant changes in
thyroid gene expression were observed even
at the lowest concentration of NaI tested
(0.1 mg/kg/day). Many of these genes,
namely, multiple antioxidant enzymes have
Figure 3. Agglomerative clustering of treated animals (r602–r604, NaI 100 mg/kg; r622–r625, PB 100 mg/kg;
r642–r645, PTU 10 mg/kg; n = 3/group) based on individual expression values of Wnt signaling genes.
Values represent the log2 of the fold change (each animal value divided by the control mean). Log2 values
were uploaded into EPCLUST [Expression Profiler, European Bioinformatics Institute (http://www.
ebi.ac.uk/expressionproﬁler)] and clustered by Euclidean distance. Numerical values are encoded by col-
ors: red and green are used to represent positive and negative values, respectively. Individual log2 values
ranged from –2.47 to 3.26.
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Figure 4. Increased circulating TSH activates pro-
tein kinase A (PKA) via the TSH receptor and the
second-messenger cAMP in thyroid follicular cells.
Cyto c, cytochrome c. We propose that decreased
circulating thyroid hormone (T3), either by increas-
ing T4 glucoronidation (PB) or decreasing periph-
eral conversion of T4 (PTU), modulates PKCζ
activity and increases the transcription of Wnt tar-
get genes. Reactive oxygen species (ROS) gener-
ated by intracellular I2 after NaI or organic iodide
metabolism may also increase protein kinase activ-
ity or cell death dependent on the magnitude of the
oxidative stress and/or other extracellular signals.Gene expression profiles of rat thyroid toxicity
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not been characterized previously in the rat
thyroid and may prove useful as biomarkers of
iodide exposure. We also demonstrate gene
expression changes associated with thyroid
histopathology and hormone status after PB
and PTU exposures. Expression patterns of
Wnt signaling genes correlated with circulat-
ing thyroid hormone levels, thyroid histo-
pathology, and the carcinogenic potential of
PB and PTU in the rat. The potential interac-
tions between these mechanisms of thyroid
toxicity are summarized in Figure 4. We sug-
gest that organic iodides may elicit changes in
circulating hormone levels as well as cause
increases in oxidative stress in the rat thyroid.
Although excess iodide may not cause follicu-
lar cell transformation via activation of Wnt
signaling, it may enhance cytotoxicity in the
rat thyroid exacerbated by thyroid pathology
caused by fluctuations in thyroid hormone
levels. These findings, in addition to further
elucidating signaling pathways that correlate
with rat thyroid pathology, may provide useful
biomarkers for the prediction of thyroid
tumorigenesis after chronic exposure to xeno-
biotics in the rat.
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